fashion -WSS

fashion

author：Wikipedia 2025-09-05 13:33:06 - browse：93975

Roche HQ — SEBASTIEN BOZON/AFP via Getty Images

The multibillion-dollar hunt for what many drugmakers hope will be the next big immunotherapy target has had no shortage of twists and tea-leaf-reading. In the wee hours of Wednesday morning, it got another.

Roche confirmed it accidentally released interim data from a closely watched clinical trial testing whether blocking that target — a protein on T cells known as TIGIT — can enable non-small lung cancer patients to live longer than standard immunotherapy alone.

The announcement release came hours after Evercore analyst Umer Raffat emailed investors that he had found a presentation on a Roche media portal, presumably uploaded by accident.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How to save PrEP access — and even expand it
Next article： CDC's new outbreak response network to include Northeastern

WSS

Medical student insurance fails on mental health care coverage

The pink breast cancer awareness ribbon needs a redesign

FDA panel to weigh approval of NurOwn, controversial ALS drug

Ukraine and a new approach to mental health in war

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

Paying for Covid pills will soon shift to insurers

knowledge

fashion

focus

Supreme Court strikes down use of affirmative action

Why are Kaiser Permanente staff considering a strike?

Tori Bowie and the unacceptable rates of Black maternal death

Readout Newsletter: XBI biotech index, Akero Therapeutics

Apple is now the first public company to be valued at $3 trillion

Testing for cancer recurrence creates a new limbo for patients

The cancer drug shortage isn’t new — and neither are the solutions

Telehealth options flood the market as retailers push virtual care

New air purifier tech could be key to improving indoor air quality

Second xenotransplant done with gene

explore

The pink breast cancer awareness ribbon needs a redesign

Second xenotransplant done with gene

Lasker Awards 2023: Winners in biomedical research

What Congress can do to address the rural doctor shortage

EpiPen alternative approval delay highlights citizen petition issue

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

leisure time

entertainment

Wikipedia

leisure time